Cargando…
Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection
Advanced cutaneous T cell lymphomas (CTCL) including mycosis fungoides (MF) and Sézary syndrome (SS) are often difficult to manage once they become resistant to initial systemic treatment. Current systemic treatments usually provide a limited duration of disease control, leaving this an area in desp...
Autores principales: | Blackmon, Amanda L, Pinter-Brown, Lauren |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502391/ https://www.ncbi.nlm.nih.gov/pubmed/32982179 http://dx.doi.org/10.2147/DDDT.S185896 |
Ejemplares similares
-
Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome
por: Beylot‐Barry, Marie, et al.
Publicado: (2022) -
PB2345: MOGAMULIZUMAB IN MYCOSIS FUNGOIDES AND SÈZARY SYNDROME: AN ITALIAN SINGLE CENTER EXPERIENCE
por: Simula, Maria Pina, et al.
Publicado: (2023) -
Low-Dose Total Skin Electron Beam Therapy Combined With Mogamulizumab for Refractory Mycosis Fungoides and Sézary Syndrome
por: Fong, Sophia, et al.
Publicado: (2020) -
Cost–utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma
por: Muszbek, Noemi, et al.
Publicado: (2023) -
Mycosis fungoides and Sézary syndrome
por: Jonak, Constanze, et al.
Publicado: (2021)